Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03169894 · ClinicalTrials.gov registry record · Phase 1
Evaluation of the Safety, Tolerability, and Efficacy of MDGN-002 in Adults With Moderate to Severe Active Crohn's Disease or Ulcerative Colitis
A Phase 1 study, sponsored by Avalo Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT03169894 is a Phase 1 study that was terminated before completion, run by Avalo Therapeutics. The registered enrollment target is 8 participants.
The verdict
NCT03169894, a Phase 1 study, was terminated before completion, sponsored by Avalo Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This is a Phase 1b, open-label, dose-escalation, signal-finding, multi-center study. The study will evaluate the safety, tolerability, pharmacokinetics and short-term efficacy of MDGN-002 in adults with moderate to severe, active Crohn's disease or Ulcerative Colitis who have previously failed anti-tumor necrosis factor alpha (anti-TNFα) treatment.
Interventions
- DRUG MDGN-002
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2017-07-14 |
| Est. Completion | 2021-10-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03169894
The ClinicalTrials.gov registry entry for NCT03169894 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Avalo Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MDGN-002 is the first listed.
NCT03169894 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03169894 about?
NCT03169894 is a clinical study titled "Evaluation of the Safety, Tolerability, and Efficacy of MDGN-002 in Adults With Moderate to Severe Active Crohn's Disease or Ulcerative Colitis". This is a Phase 1b, open-label, dose-escalation, signal-finding, multi-center study. The study will evaluate the safety, tolerability, pharmacokinetics and short-term efficacy of MDGN-002 in adults with moderate to severe, active Crohn's disease or Ulcerative Colitis who have previously failed anti-...
What is the current status of trial NCT03169894?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2017-07-14. Estimated completion is 2021-10-12.
What interventions are being tested in trial NCT03169894?
The interventions under investigation include: MDGN-002 (DRUG).
Who is sponsoring clinical trial NCT03169894?
This trial is sponsored by Avalo Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.